A Nutritional Formulation for Cognitive Performance in Mild Cognitive Impairment: A Placebo-Controlled Trial with an Open-Label Extension

Journal of Alzheimer's Disease

Volumn 48, Issue 3, 2015, Pages 591-595

  Remington, Ruth ^a   Lortie, Jevin J ^b   Hoffmann, Heather ^b   Page, Robert ^c   Morrell, Christopher ^c   Shea, Thomas B ^d  

^a FRAMINGHAM STATE UNIVERSITY   (United States)

^b KNOX COLLEGE   (United States)

^c LOYOLA UNIVERSITY MARYLAND   (United States)

^d University of Massachusetts Lowell   (United States)

Author keywords

Aging; Alzheimer's disease; cognitive performance; dementia; mild cognitive impairment; nutraceutical

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; CYANOCOBALAMIN; FOLIC ACID; LEVACECARNINE; PLACEBO; S ADENOSYLMETHIONINE;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; EFFECT SIZE; EXECUTIVE FUNCTION; HUMAN; MAJOR CLINICAL STUDY; MILD COGNITIVE IMPAIRMENT; OPEN STUDY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; TASK PERFORMANCE; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; AGED; COHORT ANALYSIS; DIET THERAPY; DIETARY SUPPLEMENT; FOLLOW UP; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

AGED; COHORT STUDIES; DIETARY SUPPLEMENTS; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; PSYCHIATRIC STATUS RATING SCALES; TREATMENT OUTCOME;

EID: 84943811026     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-150057     Document Type: Article

References (23)

1. LangaKM, LevineDA(2014) The diagnosis and management of mild cognitive impairment: A clinical review. JAMA 312, 2551-2561.
2. Croisile B, Auriacombe S, Etcharry-Bouyx F, Vercelletto M (2012) The new 2011 recommendations of the National Institute on Aging and the Alzheimer's Association on diagnostic guidelines for Alzheimer's disease: Preclinical stages, mild cognitive impairment, and dementia. Rev Neurol 168, 471-482.
3. Shea TB, Remington R (2015) Nutritional supplementation for Alzheimer's disease? Curr Opion Psychiatry 28, 141-147.
4. Shea TB, Rogers E, Remington R (2012) Nutrition and Dementia: Are we asking the right questions? J Alzheimers Dis 28, 423-431.
5. Morris MC, Tangney CC (2011) A potential design flaw of randomized trials of vitamin supplements. JAMA 305, 1348-1349.
6. Chiu S, Woodbury-Fariña MA, Shad MU, Husni M, Copen J, BureauY, CernovskyZ, Hou JJ, Raheb H, Terpstra K, Sanchez V, Hategan A, Kaushal M, Campbell R (2014) The role of nutrient-based epigenetic changes in buffering against stress, aging, and Alzheimer's disease. Psychiatr Clin North Am 37, 591-623.
7. Chan A, Paskavitz J, Remington R, Shea TB (2008) Efficacy of a vitamin/nutriceutical formulation for early-stage Alzheimer's disease: A one-year open-label pilot study with a 16-month extension. Am J Alzheimers Dis Other Demen 23, 571-585.
8. Remington R, Chan A, Shea TB (2009) Efficacy of a vitamin/nutriceutical formulation for moderate to late-stage Alzheimer's disease: A placebo-controlled pilot study. Am J Alzheimers Dis Other Demen 24, 27-33.
9. Remington R, Bechtel C, Larsen D, Samar A, Doshanjh L, Fishman P, Luo Y, Smyers K, Page R, Morrell C, Shea TB (2015) A phase II randomized clinical trial of a nutritional formulation for cognition and mood in Alzheimer's disease. J Alzheimers Dis 45, 395-405.
10. Chan A, Lepore A, Kotoya E, Zemianek J, Remington R, Shea TB (2010) Efficacy of a vitamin/nutriceutical formulation on cognitive speed and recall in adults with no known or suspected dementia. J Nutri Health Aging 14, 224-230.
11. Mischoulon D, Fava M (2002) Role of S-adenosyl-L methionine in the treatment of depression: A review of the evidence. Am J Clin Nutr 76, 1158S-1161S.
12. Royall DR, Cordes JA, Polk M (1998) CLOX: An executive clock drawing test. J Neurol Neurosurg Psychiatry 64, 588-594.
13. Monsch AU, Bondi MW, Salmon DP, Butters N, Thal LJ, Hansen LA, Wiederholt WC, Cahn DA, Klauber MR (1995) Clinical validity of the Mattis Dementia Rating Scale in detecting Dementia of the Alzheimer type. A double crossvalidation and application to a community-dwelling sample. Arch Neurol 52, 899-904.
14. Aretouli E, Brandt J (2010) Everyday functioning in mild cognitive impairment and its relationship with executive cognition. Int J Geriatr Psychiatry 25, 224-233.
15. Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos J-M, Lyketsos CG (2011) Neuropsychiatric symptoms in MCI subtypes: The importance of executive dysfunction. Int J Geriatr Psychiatry 26, 364-372.
16. Cohen J (1992) A power primer. Psychol Bull 112, 155-159.
17. Cooper C, Sommerlad A, Lyketsos CG, Livingston G (2015) Modifiable predictors of dementia in mild cognitive impairment: A systematic review and meta-analysis. Am J Psychiatry 172, 323-334.
18. Summers MJ, Saunders NL (2012) Neuropsychological measures predict decline to Alzheimer's dementia from mild cognitive impairment. Neuropsychology 26, 498-508.
19. Brusse A, Hensel A, Guhne U, Angermeyer C, Riedel-Heller SG (2006) Mild cognitive impairment: Long-term course of four clinical subtypes. Neurology 67, 2176-2185.
20. YaffeK, Petersen RC, Lindquist K, Kramer J, Miller B (2006) Subtype of mild cognitive impairment and progression to dementia and death dementia. Dement Geriatr Cogn Disord 22, 312-319.
21. de Jager CA, Oulhaj A, Jacoby R, Refsum H, Smith AD (2012) Cognitive and clinical outcomes of homocysteinelowering B-vitamin treatment in mild cognitive impairment: A randomized controlled trial. Int J Geriatr Psychiatry 27, 592-600.
22. Solfrizzi V, Frisardi V, Seripa D, Logroscino G, Imbimbo BP, D'Onofrio G, Addante F, Sancarlo D, Cascavilla L, Pilotto A, Panza F (2011) Mediterranean diet in predementia and dementia syndromes. Curr Alzheimer Res 8, 520-542.
23. Wang C, Yu JT, Wang HF, Tan CC, Meng XF, Tan L (2014) Non-pharmacological interventions for patients with mild cognitive impairment: A meta-analysis of randomized controlled trials of cognition-based and exercise interventions. J Alzheimers Dis 42, 663-678.